Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment

American Academy of Dermatology Association Task Force on Drug Pricing and Transparency, Joerg Albrecht, Adewole Adamson, John S. Barbieri, Daniel D. Bennett, Elizabeth A. Kiracofe, A. Shadi Kourosh, Kieron S. Leslie, Joseph F. Merola, Josephine Nguyen, Elaine Siegfried, Nicole Strickland, Suzanne Olbricht, Maryam M. Asgari

Research output: Contribution to journalEditorial

LanguageEnglish (US)
Pages577-578
Number of pages2
JournalJournal of the American Academy of Dermatology
Volume80
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

United States Food and Drug Administration

ASJC Scopus subject areas

  • Dermatology

Cite this

Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment. / American Academy of Dermatology Association Task Force on Drug Pricing and Transparency.

In: Journal of the American Academy of Dermatology, Vol. 80, No. 2, 01.02.2019, p. 577-578.

Research output: Contribution to journalEditorial

American Academy of Dermatology Association Task Force on Drug Pricing and Transparency 2019, 'Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment', Journal of the American Academy of Dermatology, vol. 80, no. 2, pp. 577-578. https://doi.org/10.1016/j.jaad.2018.09.016
American Academy of Dermatology Association Task Force on Drug Pricing and Transparency. / Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment. In: Journal of the American Academy of Dermatology. 2019 ; Vol. 80, No. 2. pp. 577-578.
@article{b0325756a81b425cae4955b9f0631eb8,
title = "Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment",
author = "{American Academy of Dermatology Association Task Force on Drug Pricing and Transparency} and Joerg Albrecht and Adewole Adamson and Barbieri, {John S.} and Bennett, {Daniel D.} and Kiracofe, {Elizabeth A.} and Kourosh, {A. Shadi} and Leslie, {Kieron S.} and Merola, {Joseph F.} and Josephine Nguyen and Elaine Siegfried and Nicole Strickland and Suzanne Olbricht and Asgari, {Maryam M.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.jaad.2018.09.016",
language = "English (US)",
volume = "80",
pages = "577--578",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment

AU - American Academy of Dermatology Association Task Force on Drug Pricing and Transparency

AU - Albrecht, Joerg

AU - Adamson, Adewole

AU - Barbieri, John S.

AU - Bennett, Daniel D.

AU - Kiracofe, Elizabeth A.

AU - Kourosh, A. Shadi

AU - Leslie, Kieron S.

AU - Merola, Joseph F.

AU - Nguyen, Josephine

AU - Siegfried, Elaine

AU - Strickland, Nicole

AU - Olbricht, Suzanne

AU - Asgari, Maryam M.

PY - 2019/2/1

Y1 - 2019/2/1

UR - http://www.scopus.com/inward/record.url?scp=85059752145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059752145&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2018.09.016

DO - 10.1016/j.jaad.2018.09.016

M3 - Editorial

VL - 80

SP - 577

EP - 578

JO - Journal of the American Academy of Dermatology

T2 - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 2

ER -